Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Recruiting Observational

Technique and Preliminary Results of Medial Epicondyle Fracture Fixation Using Anchors and Review of the Literature

NCT07342959 · tracked via the Priya Life Science France tracker
Phase
Observational
Started
2025-07-15
Last updated
2026-01-15

Condition(s) studied

Medial Epicondyle Fractures of the Elbow

Study summary

Medial epicondyle fractures of the humerus account for 11 to 20% of elbow fractures in children and adolescents.

The therapeutic strategy remains controversial, ranging from conservative treatment to surgical fixation depending on the degree of displacement and joint instability.

Conventional surgical management of these fractures generally involves fixation with screws or pins. However, the occurrence of certain complications, such as hardware migration, soft tissue irritation, the risk of iatrogenic comminution of small bone fragments, and the need for implant removal, has led to the exploration of alternatives, including the use of anchor fixation.

This technique involves inserting an anchor with sutures into the bone to ensure stable fixation of the fragment, while reducing the risk of comminution and avoiding the need for subsequent removal of the material.

Eligibility

Sex
ALL
Min age
1 Year
Max age
14 Years
Healthy volunteers
No
Inclusion Criteria: * Minor patient (under 15 years of age) * Admitted for recent displaced fractures of the medial epicondyle of the elbow * Treated in the pediatric surgery department at Hautepierre Hospital * Fractures requiring surgical treatment with anchor fixation. Exclusion Criteria: * Non-displaced fractures * Open fractures and associated fractures

Primary outcome measure(s)

  • Mayo Elbow Performance Score (MEPS) — Up to 12 months
    What the Mayo Performance Status (MEPS) measures: It assigns points (out of 100) based on: * Pain * Elbow mobility * Stability * Ability to perform everyday activities Interpretation of results: * 90-100 points: Excellent * 75-89 points: Good * 60-74 points: Average * \<60 points: Poor

Trial sites (1)

FacilityCityRegionStatus
Service de Chirurgie Pédiatrique - CHU de Strasbourg - France Strasbourg France Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07342959 on ClinicalTrials.gov ↗ ← All trials in France